Literature DB >> 27825850

The role of α-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling.

Arti V Shinde1, Claudio Humeres1, Nikolaos G Frangogiannis2.   

Abstract

Cardiac myofibroblasts play an important role in myocardial remodeling. Although α-smooth muscle actin (α-SMA) expression is the hallmark of mature myofibroblasts, its role in regulating fibroblast function remains poorly understood. We explore the effects of the matrix environment in modulating cardiac fibroblast phenotype, and we investigate the role of α-SMA in fibroblast function using loss- and gain-of-function approaches. In murine myocardial infarction, infiltration of the infarct border zone with abundant α-SMA-positive myofibroblasts was associated with scar contraction. Isolated cardiac fibroblasts cultured in plates showed high α-SMA expression localized in stress fibers, exhibited activation of focal adhesion kinase (FAK), and synthesized large amounts of extracellular matrix proteins. In contrast, when these cells were cultured in collagen lattices, they exhibited marked reduction of α-SMA expression, negligible FAK activation, attenuated collagen synthesis, and increased transcription of genes associated with matrix metabolism. Transforming Growth Factor-β1-mediated contraction of fibroblast-populated collagen pads was associated with accentuated α-SMA synthesis. In contrast, serum- and basic Fibroblast Growth Factor-induced collagen pad contraction was associated with reduced α-SMA expression. α-SMA siRNA knockdown attenuated contraction of collagen pads populated with serum-stimulated cells. Surprisingly, α-SMA overexpression also reduced collagen pad contraction, suggesting that α-SMA is not sufficient to promote contraction of the matrix. Reduced contraction by α-SMA-overexpressing cells was associated with attenuated proliferative activity, in the absence of any effects on apoptosis. α-SMA may be implicated in contraction and remodeling of the extracellular matrix, but is not sufficient to induce contraction. α-SMA expression may modulate cellular functions, beyond its effects on contractility.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Extracellular matrix; Myocardial infarction; Myofibroblast; Transforming growth factor-β; α-Smooth muscle actin

Mesh:

Substances:

Year:  2016        PMID: 27825850      PMCID: PMC5163362          DOI: 10.1016/j.bbadis.2016.11.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  59 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

Review 2.  The myofibroblast, a key cell in normal and pathological tissue repair.

Authors:  Ian A Darby; Noraina Zakuan; Fabrice Billet; Alexis Desmoulière
Journal:  Cell Mol Life Sci       Date:  2015-12-17       Impact factor: 9.261

3.  Contractile cells in rat myocardial scar tissue.

Authors:  R Vracko; D Thorning
Journal:  Lab Invest       Date:  1991-08       Impact factor: 5.662

4.  Smooth muscle actin determines mechanical force-induced p38 activation.

Authors:  Jiaxu Wang; Jennie Fan; Carol Laschinger; Pamela D Arora; Andras Kapus; Arun Seth; Christopher A McCulloch
Journal:  J Biol Chem       Date:  2004-12-09       Impact factor: 5.157

5.  Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fibroblasts.

Authors:  Wei Chen; Amit Saxena; Na Li; Jinyu Sun; Amit Gupta; Dong-Wook Lee; Qi Tian; Marcin Dobaczewski; Nikolaos G Frangogiannis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-20       Impact factor: 8.311

6.  Hic-5 is required for myofibroblast differentiation by regulating mechanically dependent MRTF-A nuclear accumulation.

Authors:  Scott D Varney; Courtney B Betts; Rui Zheng; Lei Wu; Boris Hinz; Jiliang Zhou; Livingston Van De Water
Journal:  J Cell Sci       Date:  2016-01-12       Impact factor: 5.285

7.  Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation.

Authors:  David Lagares; Oscar Busnadiego; Rosa Ana García-Fernández; Mohit Kapoor; Shangxi Liu; David E Carter; David Abraham; Xu Shi-Wen; Patricia Carreira; Benjamin A Fontaine; Barry S Shea; Andrew M Tager; Andrew Leask; Santiago Lamas; Fernando Rodríguez-Pascual
Journal:  Arthritis Rheum       Date:  2012-05

8.  Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase.

Authors:  Victor J Thannickal; Daniel Y Lee; Eric S White; Zongbin Cui; Jose M Larios; Raquel Chacon; Jeffrey C Horowitz; Regina M Day; Peedikayil E Thomas
Journal:  J Biol Chem       Date:  2003-01-16       Impact factor: 5.157

9.  Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart.

Authors:  Hind Lal; Firdos Ahmad; Jibin Zhou; Justine E Yu; Ronald J Vagnozzi; Yuanjun Guo; Daohai Yu; Emily J Tsai; James Woodgett; Erhe Gao; Thomas Force
Journal:  Circulation       Date:  2014-06-04       Impact factor: 29.690

Review 10.  Cardiac fibroblast in development and wound healing.

Authors:  Arjun Deb; Eric Ubil
Journal:  J Mol Cell Cardiol       Date:  2014-03-10       Impact factor: 5.000

View more
  117 in total

1.  MSC-released TGF-β regulate α-SMA expression of myofibroblast during wound healing.

Authors:  Agung Putra; Iffan Alif; Nurfitriani Hamra; Octyana Santosa; Azizah Retno Kustiyah; Adi Muradi Muhar; Kiki Lukman
Journal:  J Stem Cells Regen Med       Date:  2020-12-11

Review 2.  LncRNAs and miRs as epigenetic signatures in diabetic cardiac fibrosis: new advances and perspectives.

Authors:  Hui Tao; Zheng-Yu Song; Xuan-Sheng Ding; Jing-Jing Yang; Kai-Hu Shi; Jun Li
Journal:  Endocrine       Date:  2018-07-27       Impact factor: 3.633

3.  Extracellular ubiquitin modulates cardiac fibroblast phenotype and function via its interaction with CXCR4.

Authors:  Stephanie L C Scofield; Christopher R Daniels; Suman Dalal; Jonathan A Millard; Mahipal Singh; Krishna Singh
Journal:  Life Sci       Date:  2018-09-05       Impact factor: 5.037

4.  MiR-3613-3p inhibits hypertrophic scar formation by down-regulating arginine and glutamate-rich 1.

Authors:  Lisha Li; Weiqiang Han; Yun Chen; Yuhua Chen
Journal:  Mol Cell Biochem       Date:  2020-11-09       Impact factor: 3.396

5.  Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis.

Authors:  Patricia G Oliveira; Ricard Garcia-Carbonell; Adam P Croft; Marta F Bustamante; Jeff M Smith; Ramon L Serrano; Elsa Sanchez-Lopez; Xiao Liu; Tatiana Kisseleva; Nissim Hay; Christopher D Buckley; Gary S Firestein; Anne N Murphy; Shigeki Miyamoto; Monica Guma
Journal:  Ann Rheum Dis       Date:  2018-07-30       Impact factor: 19.103

6.  Targeting the renin-angiotensin-aldosterone system in fibrosis.

Authors:  Mohammad AlQudah; Taben M Hale; Michael P Czubryt
Journal:  Matrix Biol       Date:  2020-05-16       Impact factor: 11.583

7.  Validation of diagnostic criteria and histopathological characterization of cardiac rupture in the mouse model of nonreperfused myocardial infarction.

Authors:  Anis Hanna; Arti V Shinde; Nikolaos G Frangogiannis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-09-04       Impact factor: 4.733

Review 8.  Human pluripotent stem cell-derived cardiac stromal cells and their applications in regenerative medicine.

Authors:  Martha E Floy; Taylor D Mateyka; Koji L Foreman; Sean P Palecek
Journal:  Stem Cell Res       Date:  2020-04-27       Impact factor: 2.020

Review 9.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

10.  Cell biological mechanisms in regulation of the post-infarction inflammatory response.

Authors:  Nikolaos G Frangogiannis
Journal:  Curr Opin Physiol       Date:  2017-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.